The global virus filtration market was valued at approximately USD 4.26 billion in 2022 and is projected to experience substantial growth, expanding at a compound annual growth rate (CAGR) of 10.1% from 2023 to 2030. This growth is largely fueled by the rising prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, which are expected to increase the demand for biologic therapies. According to the World Health Organization (WHO), around 422 million people worldwide are living with diabetes, with a particularly rapid rise in cases observed in low- and middle-income countries, compared to their high-income counterparts. Diabetes is linked to numerous serious health complications, including amputations, kidney failure, heart disease, strokes, and vision loss. Between 2000 and 2019, diabetes-related mortality rates rose by 3% across all age groups, with an estimated 2 million deaths in 2019 attributed to kidney disease caused by diabetes.
The COVID-19 pandemic has had a positive impact on the virus filtration market, as awareness of the critical need for sterilization in various areas—such as biopharmaceutical products, vaccines, medical devices, and air and water systems—has significantly increased. This heightened awareness is expected to drive considerable market growth in the coming years. Virus filtration is essential for ensuring the safety, efficacy, and quality of biopharmaceutical products and vaccines, while also preventing the transmission of infectious diseases.
Gather more insights about the market drivers, restrains and growth of the Virus Filtration Market
Another significant factor contributing to the market’s expansion is the increasing need for compliance with regulatory standards in drug development and manufacturing, particularly Current Good Manufacturing Practice (cGMP) regulations. Manufacturers are required to follow strict quality control processes to ensure virus safety, including monitoring raw materials, validating effective virus clearance technologies, and confirming that finished products are free from viral contamination. This regulatory adherence creates a substantial demand for virus filtration solutions in both manufacturing and research and development (R&D).
Technology Segmentation Insights
The filtration segment dominated the market in 2022, accounting for the largest revenue share. This was due to the widespread use of filtration products in the manufacturing of biologics, medical devices, and research applications. Filtration technologies offer several advantages, including the preservation of protein integrity in both final products and research samples. They also provide high levels of efficiency and purity in both laboratory and large-scale industrial settings. As a result of increased investments in R&D and continuous product innovations by industry vendors, the filtration segment is anticipated to maintain robust growth during the forecast period.
To meet the evolving needs of biopharmaceutical, biotechnology, and medical device manufacturers, companies are making significant investments in R&D. For example, in May 2023, Merck KGaA committed USD 37.5 million to biosafety testing at its Glasgow and Stirling sites in Scotland. Biosafety testing is a crucial step in the drug development and manufacturing process, ensuring that medicines are not only safe and effective but also meet stringent regulatory standards.
The chromatography segment is expected to grow at the fastest CAGR during the forecast period, driven by advancements in product technology and the growing research and production of biologics. A key development in this area was the launch of the BioSC Pilot by Novasep in June 2018, a downstream processing (DSP) system designed for pharmaceutical applications. The BioSC Pilot utilizes both batch and continuous chromatography during purification stages, specifically focusing on the removal of contaminants from biomolecules such as monoclonal antibodies (mAbs), recombinant proteins, and blood factors. This system is designed to support biomolecule purification from the pilot phase through to small-scale commercial production, facilitating more efficient and scalable manufacturing processes.
Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.
